Tafamidis meglumine - Pfizer

Drug Profile

Tafamidis meglumine - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Tafamidis free acid; Vyndaqel

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Cardiovascular therapies; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies; Amyloid polyneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase III Cardiomyopathies

Most Recent Events

  • 18 Sep 2018 Additional efficacy data from the phase III ATTR-ACT trial in cardiomyopathy released by Pfizer
  • 17 Sep 2018 Pfizer plans a phase I bioequivalence trial in Healthy volunteers in the US (PO) (NCT03662191) (EudraCT2017-004935-350)
  • 27 Aug 2018 Additonal efficacy data from a phase III ATTR-ACT trial in Cardiomyopathy (Transthyretin amyloid cardiomyopathy) released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top